Display options
Cite
Moelans CB, van Maldegem CMG, van der Wall E, et al. Copy number changes at 8p11-12 predict adverse clinical outcome and chemo- and radiotherapy response in breast cancer. Oncotarget. 2018;9(24):17078-17092doi: 10.18632/oncotarget.24904.
Moelans, C. B., van Maldegem, C. M. G., van der Wall, E., & van Diest, P. J. (2018). Copy number changes at 8p11-12 predict adverse clinical outcome and chemo- and radiotherapy response in breast cancer. Oncotarget, 9(24), 17078-17092. https://doi.org/10.18632/oncotarget.24904
Moelans, Cathy B, et al. "Copy number changes at 8p11-12 predict adverse clinical outcome and chemo- and radiotherapy response in breast cancer." Oncotarget vol. 9,24 (2018): 17078-17092. doi: https://doi.org/10.18632/oncotarget.24904
Moelans CB, van Maldegem CMG, van der Wall E, van Diest PJ. Copy number changes at 8p11-12 predict adverse clinical outcome and chemo- and radiotherapy response in breast cancer. Oncotarget. 2018 Mar 30;9(24):17078-17092. doi: 10.18632/oncotarget.24904. eCollection 2018 Mar 30. PMID: 29682206; PMCID: PMC5908307.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2018 Mar 30;9(24):17078-17092. doi: 10.18632/oncotarget.24904. eCollection 2018 Mar 30.

Copy number changes at 8p11-12 predict adverse clinical outcome and chemo- and radiotherapy response in breast cancer.

Oncotarget

Cathy B Moelans, Caroline M G van Maldegem, Elsken van der Wall, Paul J van Diest

Affiliations

  1. Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands.
  2. Department of Gynaecology, Albert Schweitzer Hospital, Dordrecht, The Netherlands.
  3. Cancer Center, University Medical Center Utrecht, Utrecht, The Netherlands.

PMID: 29682206 PMCID: PMC5908307 DOI: 10.18632/oncotarget.24904

Abstract

PURPOSE: The short arm of chromosome 8 (8p) is a frequent target of loss of heterozygosity (LOH) in cancer, and 8p LOH is commonly associated with a more aggressive tumor phenotype. The 8p11-12 region is a recurrent breakpoint area characterized by a sharp decrease in gains/amplifications and increase in allelic loss towards 8pter. However, the clustering of genomic aberrations in this region, even in the absence of proximal amplifications or distal LOH, suggests that the 8p11-12 region could play a pivotal role in oncogenesis.

RESULTS: Loss in the

MATERIAL AND METHODS: Multiplex ligation-dependent probe amplification was used to investigate copy number aberrations at 8p11-12 in 234 female breast cancers. Alterations were correlated with clinicopathologic characteristics, survival and response to therapy. Results were validated using public METABRIC data.

CONCLUSION: Allelic loss and amplification in the 8p11-12 breakpoint region predict poor survival and chemo- and radiotherapy response. Assessment of 8p11-12 gene copy number status seems to augment existing prognostic and predictive tools.

Keywords: 8p; breast cancer; loss; predictive; prognostic

Conflict of interest statement

CONFLICTS OF INTEREST The authors declare no conflicts of interest.

References

  1. Biochim Biophys Acta. 2010 Sep;1803(9):1003-12 - PubMed
  2. DNA Repair (Amst). 2008 Dec 1;7(12 ):1999-2009 - PubMed
  3. Clin Cancer Res. 2009 Jan 15;15(2):441-51 - PubMed
  4. Mech Ageing Dev. 2008 Jan-Feb;129(1-2):79-90 - PubMed
  5. Oncogene. 2010 Sep 2;29(35):4938-46 - PubMed
  6. Clin Cancer Res. 2006 Nov 15;12(22):6652-62 - PubMed
  7. Clin Cancer Res. 2013 Jul 1;19(13):3693-702 - PubMed
  8. Endocr Relat Cancer. 2010 Feb 18;17(1):215-30 - PubMed
  9. Mod Pathol. 2010 Jul;23(7):1029-39 - PubMed
  10. Oncogene. 2006 Sep 14;25(41):5693-706 - PubMed
  11. Breast Cancer Res. 2007;9(2):R23 - PubMed
  12. Oncogene. 2004 Jul 22;23(33):5697-702 - PubMed
  13. Clin Cancer Res. 2004 Aug 1;10(15):5160-7 - PubMed
  14. Oncotarget. 2017 Jan 3;8(1):379-392 - PubMed
  15. Oncogene. 1993 May;8(5):1357-64 - PubMed
  16. Cancer Res. 1993 Sep 1;53(17):3869-73 - PubMed
  17. Genes Chromosomes Cancer. 1995 Jul;13(3):186-91 - PubMed
  18. J Clin Invest. 2013 Jul;123(7):2935-47 - PubMed
  19. Cell Oncol (Dordr). 2011 Oct;34(5):475-82 - PubMed
  20. Cancer Res. 1992 Oct 1;52(19):5368-72 - PubMed
  21. Cancer Biol Ther. 2015;16(7):1080-7 - PubMed
  22. Genes Chromosomes Cancer. 1993 Jul;7(3):152-7 - PubMed
  23. Mol Cancer Res. 2012 Jan;10(1):66-74 - PubMed
  24. Proc Natl Acad Sci U S A. 2006 Jun 6;103(23 ):8822-7 - PubMed
  25. Sci Signal. 2013 Apr 02;6(269):pl1 - PubMed
  26. Gynecol Oncol. 1999 Jul;74(1):98-102 - PubMed
  27. Cancer Res. 1996 May 15;56(10):2411-6 - PubMed
  28. Sci Signal. 2014 Dec 09;7(355):ra116 - PubMed
  29. Oncogene. 2007 Feb 22;26(8):1178-87 - PubMed
  30. BMJ. 2002 Sep 21;325(7365):648-51 - PubMed
  31. Cancer. 1999 Jan 15;85(2):447-52 - PubMed
  32. J Urol. 2014 Aug;192(2):575-82 - PubMed
  33. Cancer Cell. 2016 May 9;29(5):751-766 - PubMed
  34. Nat Commun. 2014;5:3351 - PubMed
  35. Cancer Cell. 2011 Aug 16;20(2):158-72 - PubMed
  36. Mol Cancer Res. 2005 Dec;3(12):655-67 - PubMed
  37. Genes Chromosomes Cancer. 1993 Jun;7(2):85-8 - PubMed
  38. Genes Chromosomes Cancer. 1995 Jul;13(3):168-74 - PubMed
  39. Cancer Discov. 2012 May;2(5):401-4 - PubMed
  40. Cancer Biol Ther. 2008 Nov;7(11):1732-43 - PubMed
  41. Oncogene. 2009 Feb 5;28(5):752-61 - PubMed
  42. Lancet Oncol. 2014 Mar;15(3):267-74 - PubMed
  43. Cancer Res. 1993 Mar 1;53(5):1172-4 - PubMed
  44. J Neurochem. 2006 Jul;98 (1):89-101 - PubMed
  45. Cancer Res. 2010 Mar 1;70(5):2085-94 - PubMed
  46. Cell. 1997 Apr 18;89(2):215-25 - PubMed
  47. Oncogene. 2009 Nov 19;28(46):4041-52 - PubMed
  48. Oncogene. 1998 Oct 22;17(16):2107-13 - PubMed
  49. Horm Res Paediatr. 2010;74(1):33-40 - PubMed
  50. Mod Pathol. 2010 Jan;23(1):62-70 - PubMed
  51. PLoS One. 2013 Aug 26;8(8):e72053 - PubMed
  52. Nat Med. 2011 Apr;17(4):422-3 - PubMed
  53. Cancer. 2000 Mar 15;88(6):1410-6 - PubMed
  54. Mol Med Rep. 2014 Jun;9(6):2411-6 - PubMed
  55. Oncogene. 2004 Mar 18;23(12):2250-63 - PubMed
  56. Clin Cancer Res. 2013 Jun 1;19(11):2883-92 - PubMed

Publication Types